{"id":"https://openalex.org/A5092587957","orcid":"https://orcid.org/0000-0002-1773-3820","observed_orcids":["https://orcid.org/0000-0002-1773-3820"],"display_name":"John Ashkenas","raw_author_names":["Ashkenas, John","John Ashkenas"],"full_name":"John Ashkenas","works_count":4,"cited_by_count":9,"summary_stats":{"2yr_mean_citedness":0.5,"h_index":1,"i10_index":0},"ids":{"openalex":"https://openalex.org/A5092587957","orcid":"https://orcid.org/0000-0002-1773-3820","observed_orcids":["https://orcid.org/0000-0002-1773-3820"]},"affiliations":[{"institution":{"id":"https://openalex.org/I4405273080","ror":"https://ror.org/0588nm138","display_name":"Taysha Gene Therapies (United States)","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273080"]},"years":[2026]}],"last_known_institutions":[{"id":"https://openalex.org/I4405273080","ror":"https://ror.org/0588nm138","display_name":"Taysha Gene Therapies (United States)","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273080"]}],"topics":[{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","count":2,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","count":1,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10704","display_name":"Advancements in Transdermal Drug Delivery","count":1,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","count":1,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","count":1,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"topic_share":[{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","value":8.8e-06,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11872","display_name":"Barrier Structure and Function Studies","value":8e-06,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11702","display_name":"Parasitic Diseases Research and Treatment","value":7.8e-06,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11772","display_name":"Genetics and Neurodevelopmental Disorders","value":7.4e-06,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10704","display_name":"Advancements in Transdermal Drug Delivery","value":7.1e-06,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"x_concepts":[{"id":"112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","score":0.7100368738174438},{"id":"71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","score":0.6610000133514404},{"id":"181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","score":0.6188402771949768},{"id":"98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","score":0.4449392259120941},{"id":"160892712","wikidata":"https://www.wikidata.org/wiki/Q901559","display_name":"Fourier transform infrared spectroscopy","score":0.4327981173992157}],"counts_by_year":[{"year":2023,"works_count":2,"oa_works_count":2,"cited_by_count":4},{"year":2024,"works_count":0,"oa_works_count":0,"cited_by_count":1},{"year":2025,"works_count":0,"oa_works_count":0,"cited_by_count":1},{"year":2026,"works_count":2,"oa_works_count":2,"cited_by_count":3}],"display_name_alternatives":["Ashkenas, John","John Ashkenas"],"block_key":"j ashkenas","works_api_url":"https://api.openalex.org/works?filter=author.id:A5092587957","awards_count":0,"updated_date":"2026-11-07T12:08:38","created_date":"2023-08-04T00:00:00"}